Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on Imlifidase for Patients with Severe ANCA-Associated Vasculitis and Lung Bleeding

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a disease called ANCA-associated vasculitis, which is a condition where the body's immune system mistakenly attacks its own blood vessels, leading to inflammation. In this study, the specific type of ANCA-associated vasculitis being examined involves severe bleeding in the lungs, known as pulmonary hemorrhage. The treatment being tested is a medication called Idefirix, which contains an active substance named imlifidase. This medication is given through an intravenous infusion, meaning it is administered directly into the bloodstream.

The purpose of the study is to evaluate how effective Idefirix is when used alongside the standard care for patients with severe ANCA-associated vasculitis and lung bleeding. Participants in the study will receive either Idefirix or a placebo, in addition to the usual treatments for their condition. The study will monitor how quickly the levels of ANCA antibodies in the blood decrease after treatment, as well as other health outcomes such as lung and kidney function, and overall safety.

Throughout the study, researchers will observe participants for any changes in their condition, including improvements in lung function and any potential side effects. The study aims to provide valuable information on the potential benefits and safety of using Idefirix in treating this serious form of vasculitis. The trial is expected to continue until mid-2026, with recruitment of participants starting in 2024.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will provide written informed consent. This means you agree to participate after understanding the study's purpose and procedures.

    You will be assessed to ensure you meet the study's criteria, such as having a clinical diagnosis of ANCA-associated vasculitis with specific symptoms.

  2. Step 2

    Initial assessment

    A detailed medical evaluation will be conducted, including a review of your medical history and current health status.

    Tests may include blood tests to measure ANCA titers and imaging studies like chest X-rays or CT scans to assess lung involvement.

  3. Step 3

    Treatment administration

    You will receive the study medication, Idefirix, which contains the active substance imlifidase. This will be given as an intravenous infusion, meaning it is administered directly into your vein.

    The goal is to observe the effect of imlifidase on your condition, particularly its ability to reduce ANCA levels within 24 hours.

  4. Step 4

    Monitoring and follow-up

    Your health will be closely monitored throughout the study. This includes regular check-ups and tests to track your response to the treatment.

    The study will assess various outcomes, such as changes in ANCA levels, lung and kidney function, and any side effects you may experience.

  5. Step 5

    Completion of study

    At the end of the study period, a final assessment will be conducted to evaluate your overall health and the effects of the treatment.

    You will receive information about the study's findings and any further steps regarding your health care.

Who can join the trial?

11 criteria

  • Must have a new or previous clinical diagnosis of ANCA-associated vasculitis, which includes conditions like granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
  • Must have an ANCA titer (a type of blood test) of 50 or higher, measured no more than 14 days before joining the study.
  • Must have pulmonary hemorrhage (bleeding in the lungs) due to active vasculitis, confirmed by:
    • A chest x-ray or CT scan showing specific lung patterns.
    • No other explanation for lung issues, like fluid overload or infection.
    • At least one of the following:
      • Evidence of bleeding in the lungs from a bronchoscopy (a test using a camera to look inside the lungs).
      • Coughing up blood.
      • Unexplained low red blood cell count (anemia) or a drop in hemoglobin levels.
      • Acute respiratory distress syndrome (ARDS), a severe lung condition.
      • Must provide written informed consent before any study-related procedures.
      • Must be willing and able to follow the study protocol.
      • For female participants: Must be confirmed as post-menopausal, meaning no menstrual periods for at least 12 months.

Who cannot join the trial?

10 criteria

  • Patients with any other serious medical condition that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial within the last 30 days.
  • Patients with a known allergy to the study medication or its ingredients.
  • Patients with a history of drug or alcohol abuse within the past year.
  • Patients who are unable to follow the study procedures or instructions.
  • Patients with a history of non-compliance with medical treatments.
  • Patients with severe liver or kidney disease.
  • Patients with active infections that require treatment.
  • Patients with a history of cancer within the last 5 years, except for certain skin cancers.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Imlifidase is a medication being studied for its potential to help treat a condition called ANCA-associated vasculitis, which can cause severe inflammation in blood vessels. In this trial, researchers are looking at how well imlifidase works when combined with the usual treatments for this condition. The goal is to see if it can help reduce the severity of symptoms, especially in cases where there is bleeding in the lungs.

What is already known about the treatment

Imlifidase – Imlifidase is administered through an intravenous infusion, meaning it is delivered directly into the bloodstream via a vein. It is currently being studied in clinical trials for its effectiveness in treating a condition called ANCA-associated vasculitis, which can cause severe bleeding in the lungs. The medication works by breaking down specific proteins in the immune system that are involved in this disease, helping to reduce inflammation and damage. Imlifidase is classified as an enzyme-based therapy, specifically targeting the immune system to alleviate symptoms and improve patient outcomes.

Investigated diseases

Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis with severe diffuse alveolar hemorrhage – This disease is a type of vasculitis, which involves inflammation of blood vessels. It is associated with the presence of ANCA, which are antibodies that mistakenly target and attack certain proteins in the body. In this condition, the inflammation primarily affects small to medium-sized blood vessels, leading to damage. The severe form includes diffuse alveolar hemorrhage, where bleeding occurs in the tiny air sacs of the lungs. This can result in coughing up blood and difficulty breathing. The disease progresses with episodes of inflammation and bleeding, which can cause significant lung damage over time.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-516727-13-00Protocol codeImlifidARDSe.01Estimated enrolment10 patientsSponsorCharite Universitaetsmedizin Berlin KöR

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.